{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:27Z","timestamp":1792839747593,"version":"4.5.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Glecaprevir\/pibrentasvir (GLE\/PIB) has shown high efficacy and safety in chronic HCV\u2010infected adults and adolescents; data in children were limited. DORA part 2 is a phase 2\/3, nonrandomized, open\u2010label study evaluating the pharmacokinetics, efficacy, and safety of a pediatric formulation of GLE and PIB in children ages 3 to &lt; 12 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results<\/jats:title>\n                    <jats:p>Children with chronic HCV infection, genotype 1\u20106, with or without compensated cirrhosis, were divided into three cohorts by age\u2014cohort 2 (9 to &lt; 12 years), cohort 3 (6 to &lt; 9 years), and cohort 4 (3 to &lt; 6 years)\u2014and given weight\u2010based doses of GLE and PIB for 8, 12, or 16 weeks. Primary endpoints were sustained virologic response at posttreatment week 12 (SVR12) and steady\u2010state exposure; secondary endpoints were rates of persistent viremia, relapse, and reinfection. Safety and laboratory abnormalities were assessed. Final pediatric dosages determined to be efficacious were 250 mg GLE + 100 mg PIB (in children weighing \u2265 30 to &lt; 45 kg), 200 mg GLE + 80 mg PIB (\u2265 20 to &lt; 30 kg), and 150 mg GLE + 60 mg PIB (12 to &lt; 20 kg). Of 80 participants enrolled and dosed, 96% (77\/80) achieved SVR12. One participant, on the initial dose ratio, relapsed by posttreatment week 4; no participants had virologic failures on the final dose ratio of GLE 50 mg\/PIB 20 mg. Two nonresponders prematurely discontinued the study. Most adverse events (AEs) were mild; no drug\u2010related serious AEs occurred. Pharmacokinetic exposures were comparable to those of adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A pediatric formulation of GLE\/PIB was highly efficacious and well tolerated in chronic HCV\u2010infected children 3 to &lt; 12 years old.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.31841","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T01:09:50Z","timestamp":1617412190000},"page":"19-27","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":64,"title":["Pharmacokinetics, Safety, and Efficacy of Glecaprevir\/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study"],"prefix":"10.1097","volume":"74","author":[{"given":"Maureen M.","family":"Jonas","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition,Boston Children\u2019s Hospital,Boston,MA"},{"name":"Department of Pediatrics,Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Rhee","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre A.","family":"Kelly","sequence":"additional","affiliation":[{"name":"The Liver Unit,Birmingham Women\u2019s & Children\u2019s Hospital and University of Birmingham,Birmingham,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Del Valle\u2010Segarra","sequence":"additional","affiliation":[{"name":"San Jorge Children\u2019s Hospital,San Juan,Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Feiterna\u2010Sperling","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pulmonology, Immunology, and Intensive Care Medicine,Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin,Berlin,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Gilmour","sequence":"additional","affiliation":[{"name":"Stollery Children\u2019s Hospital and University of Alberta,Edmonton,AB,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regino P.","family":"Gonzalez\u2010Peralta","sequence":"additional","affiliation":[{"name":"AdventHealth for Children,AdventHealth Transplant Institute,Orlando,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Hierro","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition,Texas Children\u2019s Hospital,Houston,TX"},{"name":"Department of Pediatrics,Baylor College of Medicine,Houston,TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Ling","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition,The Hospital for Sick Children,Toronto,ON,Canada"},{"name":"Department of Paediatrics,University of Toronto,Toronto,ON,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Lobzin","sequence":"additional","affiliation":[{"name":"Pediatric Research and Clinical Center for Infectious Diseases and North\u2010Western State Medical University named after I.I. Mechnikov,Russian Federation,St. Petersburg,Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1482-1128","authenticated-orcid":false,"given":"Steven","family":"Lobritto","sequence":"additional","affiliation":[{"name":"Morgan Stanley Children\u2019s Hospital of New York,Columbia University Irving Medical Center,New York,NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Mizuochi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health,Kurume University School of Medicine,Kurume,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Narkewicz","sequence":"additional","affiliation":[{"name":"Digestive Health Institute,Children\u2019s Hospital Colorado,Section of Pediatric Gastroenterology,Hepatology, and Nutrition,Department of Pediatrics University of Colorado School of Medicine,Aurora,CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishakha","family":"Sabharwal","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases,Department of Pediatrics,Boston University Medical Center,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wen","sequence":"additional","affiliation":[{"name":"The Children\u2019s Hospital Philadelphia and University of Pennsylvania,Philadelphia,PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi","family":"Kei Lon","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marcinak","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Topp","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Tripathi","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5597-4708","authenticated-orcid":false,"given":"Etienne","family":"Sokal","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology and Hepatology,Universit\u00e9 Catholique de Louvain,Cliniques Universitaires Saint Luc,Brussels,Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"hep31841-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep31841-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MPG.0000000000001872","article-title":"Treatment of chronic hepatitis C virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"66","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"hep31841-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S2468-1253(19)30046-9","article-title":"Hepatitis C virus infection in children and adolescents","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep31841-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1053\/j.gastro.2008.02.082","article-title":"Long\u2010term course of chronic hepatitis C in children: from viral clearance to end\u2010stage liver disease","volume":"134","year":"2008","journal-title":"Gastroenterology"},{"key":"hep31841-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/MPG.0000000000002814","article-title":"Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper","volume":"71","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"hep31841-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.30830","article-title":"Ledipasvir\u2013sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C","volume":"71","year":"2020","journal-title":"Hepatology"},{"key":"hep31841-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/hep.30123","article-title":"Safety and efficacy of ledipasvir\u2013sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6\u201011","volume":"68","year":"2018","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"hep31841-bib-0013-20250824","article-title":"Safety and efficacy of sofosbuvir\/velpatasvir in pediatric patients 6 to < 18 years old with chronic hepatitis C infection","volume":"70","year":"2019","journal-title":"Hepatology"},{"key":"hep31841-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep31841-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8\u2010week and 12\u2010week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20106 patients without cirrhosis","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep31841-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment\u2010naive patients with chronic HCV genotypes 1\u20106 and compensated cirrhosis: the EXPEDITION\u20108 trial","volume":"72","year":"2020","journal-title":"J Hepatol"},{"key":"hep31841-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION\u20102 study","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"key":"hep31841-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study","volume":"71","year":"2020","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31841","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:06:39Z","timestamp":1756076799000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31841","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"2020-12-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}